ACC 2017: Late-Breaking Clinical Trials

Research includes safety of digoxin with atrial fibrillation, comparison of cerebral embolic protection devices, and cerebral microbleed triggers.

Presentations during the Late-Breaking Clinical Trials session at the American College of Cardiology’s Annual Scientific Sessions included a safety investigation of digoxin use in patients with atrial fibrillation, a study of two embolic protection devices and their abilities to prevent stroke and brain infarcts, and possible triggers of cerebral microbleeds during transacatheter aortic valve replacement.

Related Videos
© 2023 MJH Life Sciences

All rights reserved.